IL17A and cancer: Treatment may necessitate systemic therapy, and although biologics such as tumor necrosis factor alpha inhibitors are contraindicated in patients with cancer, interleukin 17 inhibitors (eg, secukinumab) may offer a promising treatment strategy for these patients.